Clinical Trial Detail

NCT ID NCT04079738
Title Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors H Scott Boswell
Indications

acute myeloid leukemia

Therapies

Ixazomib + Mivavotinib

Age Groups: adult senior

No variant requirements are available.